In a cohort of 1.055 MF patients treated with ruxolitinib, 135 with CALR mutations more frequently developed anemia and increased blast percentages [82], likely reflecting later treatment initiation, higher disease burden, and longer intervals from diagnosis, which may diminish the favorable prognostic impact of CALR mutations. The gene discussed is CALR; the disease is anemia.